A recent study reveals that the active component found in Wegovy and Ozempic, popular medications for type-2 diabetes, could potentially lower the risk of Alzheimer’s disease among patients. This groundbreaking research conducted by experts at Case Western Reserve School of Medicine highlights the benefits of semaglutide compared to other anti-diabetic drugs. The results were consistent across various subgroups, indicating promising outcomes for patients dealing with type-2 diabetes. Semaglutide belongs to a class of drugs that mimic the body’s natural GLP-1 hormone, aiding in hunger reduction and blood sugar regulation for individuals with type-2 diabetes. Approved by the FDA for treating type-2 diabetes since 2017 and weight loss since 2021, semaglutide has shown a significant decrease (40% to 70%) in first-time Alzheimer’s diagnoses compared to alternative anti-diabetic medications. This real-world evidence supports previous preclinical research suggesting that semaglutide may offer protection against neurodegeneration and neuroinflammation associated with Alzheimer’s disease. With Alzheimer’s ranking as the seventh-leading cause of death in the US, affecting thousands annually according to CDC data, these findings hold immense promise for improving patient outcomes.
2024-12-19 11:15:02
Post from www.ibtimes.com
